Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy
T Lei, Y Wang, Y Zhang, Y Yang, J Cao, J Huang… - Leukemia, 2024 - nature.com
Abstract Chimeric Antigen Receptor (CAR)-T-cell therapy has revolutionized cancer immune
therapy. However, challenges remain including increasing efficacy, reducing adverse events …
therapy. However, challenges remain including increasing efficacy, reducing adverse events …
CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells
T Bexte, N Albinger, A Al Ajami, P Wendel… - Nature …, 2024 - nature.com
Chimeric antigen receptor (CAR)-modified natural killer (NK) cells show antileukemic activity
against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is …
against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is …
Synthetic cells and molecules in cellular immunotherapy
Cellular immunotherapy has emerged as an exciting strategy for cancer treatment, as it aims
to enhance the body's immune response to tumor cells by engineering immune cells and …
to enhance the body's immune response to tumor cells by engineering immune cells and …
The Fate (s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy
M Abou-el-Enein - Blood Cancer Discovery, 2024 - AACR
The introduction of chimeric antigen receptor (CAR) T-cell therapy represents a landmark
advancement in treating resistant forms of cancer such as leukemia, lymphoma, and …
advancement in treating resistant forms of cancer such as leukemia, lymphoma, and …
[HTML][HTML] Current Non-Viral-Based Strategies to Manufacture CAR-T Cells
L Gehrke, VDR Gonçalves, D Andrae, T Rasko… - International journal of …, 2024 - mdpi.com
The successful application of CAR-T cells in the treatment of hematologic malignancies has
fundamentally changed cancer therapy. With increasing numbers of registered CAR-T cell …
fundamentally changed cancer therapy. With increasing numbers of registered CAR-T cell …
Blood cancer therapy with synthetic receptors and CRISPR technology
H Zhang, M Zhong, J Zhang, C Chen - Leukemia Research, 2025 - Elsevier
Chimeric antigen receptor (CAR)-T and-NK cells showed great success in treating
hematological malignancies, including leukemia, lymphoma, and myeloma. CRISPR …
hematological malignancies, including leukemia, lymphoma, and myeloma. CRISPR …
Empowering virus-free CAR immune cell therapies
Immune cell therapies with chimeric antigen receptor (CAR)-T and natural killer (NK) cells
have demonstrated groundbreaking therapeutic effects in hematological malignancies in the …
have demonstrated groundbreaking therapeutic effects in hematological malignancies in the …
CAR-T cell therapy: recent updates and challenges in autoimmune diseases
B Caël, E Bôle-Richard, F Garnache-Ottou… - Journal of Allergy and …, 2024 - Elsevier
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the treatment of
hematological malignancies, demonstrating significant clinical efficacy and leading to FDA …
hematological malignancies, demonstrating significant clinical efficacy and leading to FDA …
Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells
AM Nitulescu, W Du, V Glaser, J Kath, R Greensmith… - bioRxiv, 2024 - biorxiv.org
Non-viral gene editing via CRISPR-Cas12a offers an alternative to Cas9-based methods,
providing better targeting of AT-rich regions, simplified guide RNA manufacturing, and high …
providing better targeting of AT-rich regions, simplified guide RNA manufacturing, and high …
Putting together the pieces: CAR into CD3ζ locus
M Casucci - Blood, 2024 - ashpublications.org
In this issue of Blood, Kath et al 1 report a novel virus-free strategy to redirect cell specificity
via in-frame integration of CD3ζ-deficient chimeric antigen receptors (CARs) within the CD3ζ …
via in-frame integration of CD3ζ-deficient chimeric antigen receptors (CARs) within the CD3ζ …